UY34048A - Proteínas de repetición enlazantes de il4/il13 y sus usos - Google Patents

Proteínas de repetición enlazantes de il4/il13 y sus usos

Info

Publication number
UY34048A
UY34048A UY0001034048A UY34048A UY34048A UY 34048 A UY34048 A UY 34048A UY 0001034048 A UY0001034048 A UY 0001034048A UY 34048 A UY34048 A UY 34048A UY 34048 A UY34048 A UY 34048A
Authority
UY
Uruguay
Prior art keywords
binding
repetition
proteins
inhibit
diseases
Prior art date
Application number
UY0001034048A
Other languages
English (en)
Inventor
Jacobs Steven
Karyn O'neil
Baumann Michael
Sennauser Gaby
Original Assignee
Janssen Biotech Inc
Molecular Partners
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc, Molecular Partners filed Critical Janssen Biotech Inc
Publication of UY34048A publication Critical patent/UY34048A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Las proteínas de unión a IL4/IL13 comprenden dominios de unión, que inhiben la unión de IL4/IL13 a IL4Ralpaha y complejos de cadena gamma comunes (Tipo 1) s e inhiben la unión de IL4 a complejos de IL4Ralpha y IL13Ralphal (Tipo 2), y la unión de IL13 a IL13Ralphal y/o IL13Ralpha2, son útiles en el tratamiento de cáncer, enfermedades inflamatorias y otras enfermedades patológicas, tales como condiciones alérgicas o fibróticas, especialmente enfermedades pulmonares
UY0001034048A 2011-04-29 2012-04-30 Proteínas de repetición enlazantes de il4/il13 y sus usos UY34048A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161481008P 2011-04-29 2011-04-29
US201161480999P 2011-04-29 2011-04-29
US201161481021P 2011-04-29 2011-04-29

Publications (1)

Publication Number Publication Date
UY34048A true UY34048A (es) 2012-10-31

Family

ID=47068346

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034048A UY34048A (es) 2011-04-29 2012-04-30 Proteínas de repetición enlazantes de il4/il13 y sus usos

Country Status (14)

Country Link
US (2) US8722618B2 (es)
EP (1) EP2702069A4 (es)
JP (1) JP2014519808A (es)
KR (1) KR20140039203A (es)
CN (1) CN104105704A (es)
AR (1) AR086241A1 (es)
AU (1) AU2012249359A1 (es)
BR (1) BR112013027766A2 (es)
CA (1) CA2834624A1 (es)
EA (1) EA201391607A1 (es)
IL (1) IL229093A0 (es)
TW (1) TW201305337A (es)
UY (1) UY34048A (es)
WO (1) WO2012149439A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
CA2818990C (en) 2010-11-26 2021-06-15 Molecular Partners Ag Designed repeat proteins binding to serum albumin
BR112014032316A2 (pt) * 2012-06-28 2017-06-27 Molecular Partners Ag proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
WO2014191574A1 (en) * 2013-05-31 2014-12-04 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor
KR20150097304A (ko) 2014-02-18 2015-08-26 삼성전자주식회사 항 EGFR DARPin을 포함하는 EGFR/HER2 이중 특이 항체
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
ES2953482T3 (es) 2015-04-02 2023-11-13 Molecular Partners Ag Dominios de repetición de anquirina diseñados con especificidad de unión para la albúmina sérica
MX2019003298A (es) 2016-09-22 2019-09-26 Molecular Partners Ag Proteinas de union recombinantes y sus usos.
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP2020517262A (ja) * 2017-04-21 2020-06-18 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子
KR102676582B1 (ko) * 2018-07-25 2024-06-20 주식회사유한양행 갑상선 자극 호르몬 수용기(thyrotropin receptor, TSHR) 단편을 포함하는 융합 단백질 및 이의 용도
WO2020190852A2 (en) * 2019-03-17 2020-09-24 Jorge Fallas Topological control of receptor signaling using synthetic homo- and hetero-dimeric cytokine mimetics
BR112021024231A2 (pt) * 2019-06-04 2022-04-26 Molecular Partners Ag Proteínas de ligação fap recombinantes e uso da mesma
EP4028413A1 (en) 2019-09-10 2022-07-20 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
AU2020399230A1 (en) 2019-12-11 2022-06-23 Molecular Partners Ag Recombinant peptide-MHC complex binding proteins and their generation and use
CR20220618A (es) 2020-05-06 2023-01-19 Molecular Partners Ag Nuevas proteinas de unión a repeticiones de anquirina y sus usos
MX2023010543A (es) 2021-03-09 2023-10-13 Molecular Partners Ag Ligadores multiespecificos de celulas t novedosos basados en darpin.
CN116789843A (zh) * 2022-03-16 2023-09-22 伯桢生物科技(杭州)有限公司 Wnt重组蛋白及其应用
WO2024059686A2 (en) * 2022-09-15 2024-03-21 The Regents Of The University Of California Darpin backbones and rigidified electron microscopy imaging scaffolds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1892296A1 (en) 1988-09-02 2008-02-27 Dyax Corporation Generation and selection of recombinant varied binding proteins
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
JP4086325B2 (ja) 1997-04-23 2008-05-14 プリュックテュン，アンドレアス 標的分子と相互作用する（ポリ）ペプチドをコードする核酸分子の同定方法
US6416950B1 (en) 1998-12-02 2002-07-09 Phylos, Inc. DNA-protein fusions and uses thereof
WO2002020565A2 (en) * 2000-09-08 2002-03-14 Universität Zürich Collections of repeat proteins comprising repeat modules
US7875465B2 (en) * 2005-05-31 2011-01-25 Canon Kabushiki Kaisha Target substance capturing molecule
NZ564695A (en) 2005-07-08 2009-02-28 Univ Zuerich Phage display using cotranslational translocation of fusion polypeptides
WO2009138413A1 (en) * 2008-05-15 2009-11-19 Domantis Limited Single domain antibodies that bind il-13
WO2008048008A1 (en) 2006-10-16 2008-04-24 Jason R & D Co., Ltd. System for transmitting information to be added to contents and method for using the same
EP2263088A2 (en) * 2008-03-19 2010-12-22 Institut Pasteur Reagentless fluorescent biosensors comprising a designed ankyrin repeat protein module, rational design methods to create reagentless fluorescent biosensors and methods of their use
JP5954990B2 (ja) 2008-11-03 2016-07-20 モレキュラー・パートナーズ・アーゲーＭｏｌｅｃｕｌａｒ Ｐａｒｔｎｅｒｓ Ａｇ Ｖｅｇｆ−ａレセプター相互作用を阻害する結合タンパク質

Also Published As

Publication number Publication date
US8722618B2 (en) 2014-05-13
TW201305337A (zh) 2013-02-01
US20120277143A1 (en) 2012-11-01
AU2012249359A1 (en) 2013-11-14
IL229093A0 (en) 2013-12-31
CA2834624A1 (en) 2012-11-01
BR112013027766A2 (pt) 2016-11-29
KR20140039203A (ko) 2014-04-01
AR086241A1 (es) 2013-11-27
CN104105704A (zh) 2014-10-15
EP2702069A2 (en) 2014-03-05
US9206244B2 (en) 2015-12-08
WO2012149439A3 (en) 2014-05-30
EA201391607A1 (ru) 2014-04-30
WO2012149439A2 (en) 2012-11-01
JP2014519808A (ja) 2014-08-21
EP2702069A4 (en) 2015-04-29
US20140206599A1 (en) 2014-07-24

Similar Documents

Publication Publication Date Title
UY34048A (es) Proteínas de repetición enlazantes de il4/il13 y sus usos
CR20130134A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
CO6710907A2 (es) Anticuerpos que se unen específicamente a cd33 que son útiles en el tratamiento de trastornos de células mieloides y del síndrome mielodisplásico (msd)
MA43377A (fr) Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire
CY1117372T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες και η χρηση τους
CY1118859T1 (el) 6-αλκινυλο-πυριδινες ως μιμητες smac
CR20120154A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
GT201400066A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
CO6670585A2 (es) Promotores de apotosis n-acilsufonamidas
GT201300160A (es) Inmunoglobulinas de dominio variable dual biespecificas de il-1 alfa y beta y su uso
GT201200314A (es) Agentes inductores de apoptosis para el tratamiento de cáncer y de enfermedades inmunes y autoinmunes
EA201491856A1 (ru) Терапевтическое применение белков фактора роста фибробластов 21
EA201591767A8 (ru) Композиции, обеспечивающие пропускание экзонов, для лечения мышечной дистрофии
CR20110631A (es) Inmunoglobulina con dominio variable dual y usos de la misma
UY33826A (es) Proteínas de unión con dominios trivariables y sus usos
ECSP13012648A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
DOP2013000025A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
UY34683A (es) Esteviol glucosiltransferasas y genes que las codifican
IN2015DN02032A (es)
CO6950477A2 (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
BR112012020700A2 (pt) método de tratamento de paciente diagnosticadas com câncer do ovário kit de tratamento de cânce do ovario metodo de instrução a uma paciente humana com cãncer do ovario método promocionale comercial
CR20160285A (es) Inhibidores de quinasa relacionada con la tropomiosina (trk)
MX2015016120A (es) Moleculas de union que se adhieren al factor de complemento c2 humano y usos de los mismos.
EA201390867A1 (ru) Композиции на основе глины и обножки, способ их получения и их применение в питании и терапевтическом лечении
DK3052109T3 (da) Terapi med celler fra human placenta og hematopoietiske celler